Literature DB >> 26502757

Myasthenia Gravis.

Kelly G Gwathmey1, Ted M Burns1.   

Abstract

Myasthenia gravis is an autoimmune neuromuscular disease caused by antibodies directed against the postsynaptic muscle membrane. The clinical hallmark of the disease is fluctuating and fatigable weakness that affects the ocular muscles (resulting in diplopia and ptosis), the bulbar muscles (causing dysphagia, dysarthria, and dyspnea), and extremity muscles. The diagnosis is most often made with serological testing that identifies either acetylcholine receptor antibodies or muscle-specific tyrosine kinase antibodies. Electrodiagnostic testing has a role in supporting the diagnosis. There are many available treatments that result in improvement of function and quality of life. Treatment should be individualized after consideration of many factors, including disease distribution and severity, patient comorbidities, age, serological status, and what is known about the efficacy and safety of the various treatments. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26502757     DOI: 10.1055/s-0035-1558975

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  11 in total

Review 1.  Adalimumab-induced myasthenia gravis: case-based review.

Authors:  Eleftherios Pelechas; Tereza Memi; Theodora E Markatseli; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2020-04-22       Impact factor: 2.631

2.  Anti-Musk Positive Myasthenia Gravis and Three Semiological Cardinal Signs.

Authors:  André P C Matta; Ana C Andorinho F Ferreira; Arielle Kirmse; Anna Carolina Damm; João Gabriel D I B Farinhas; Mariane D Barbosa; Mayara C M Teles; Camila Fiorelli; Rossano Fiorelli; Osvaldo J M Nascimento; Marco Orsini
Journal:  Neurol Int       Date:  2014-01-05

3.  Acute exacerbation of myasthenia gravis with topical imiquimod use.

Authors:  Saadeddine Saad; Bobbak Mansouri; Chad Housewright
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

4.  Starvation-induced diplopia and weakness: a case of beriberi and Wernicke's encephalopathy.

Authors:  Timothy Xin Zhong Tan; Kheng Choon Lim; Charles Chan Chung; Than Aung
Journal:  BMJ Case Rep       Date:  2019-01-03

Review 5.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

6.  Characterization of patients with ocular myasthenia gravis - A case series.

Authors:  Arnon Karni; Ali Asmail; Vivian E Drory; Hadar Kolb; Anat Kesler
Journal:  eNeurologicalSci       Date:  2016-04-25

7.  Correlation Between Thymus Radiology and Myasthenia Gravis in Clinical Practice.

Authors:  Huan Luo; Shanshan Xie; Chao Ma; Wenqiang Zhang; Carsten Tschöpe; Xianen Fa; Jingliang Cheng; Jing Cao
Journal:  Front Neurol       Date:  2019-01-15       Impact factor: 4.003

8.  Fecal microbiota profile in a group of myasthenia gravis patients.

Authors:  German Moris; Silvia Arboleya; Leonardo Mancabelli; Christian Milani; Marco Ventura; Clara G de Los Reyes-Gavilán; Miguel Gueimonde
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379

9.  High-Resolution Esophageal Manometry in Myasthenia Gravis.

Authors:  Gustavo Torres-Barrera; Gilberto Herrera-Quiñones; Susana Isabel Scharrer; Daniel Eduardo Benavides-Salgado; Hector Jesus Maldonado-Garza; Sami Rene Achem
Journal:  ACG Case Rep J       Date:  2020-03-16

10.  Oral function in patients with myasthenia gravis.

Authors:  Agnete Overgaard Donskov; Akiko Shimada; Lotte Vinge; Peter Svensson; Henning Andersen
Journal:  PeerJ       Date:  2021-06-29       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.